Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from Merck & Co, Inc.

Melanoma: At the Forefront of Emerging Immunotherapy Approaches in Cancer Care

Release Date: January 29, 2021
Expiration Date: January 29, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in melanoma. In this educational program, these experts provide updates to the management of melanoma across the disease continuum, including resectable disease, metastatic disease, and in later lines of therapy. Faculty provide their perspectives and best practices, in addition to forecasting treatment options on the horizon.

This educational activity is an archive of the live virtual symposium held on January 12, 2021.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Merck & Co, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists who treat patients with melanoma. Dermatologists, pathologists, histologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of melanoma will be invited to participate.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Assess strategies to improve patient selection for neoadjuvant and adjuvant systemic therapies in resectable melanoma
  • Evaluate recent safety and efficacy data regarding immunotherapy as a single agent or in combination strategies in the treatment of melanoma
  • Apply recent data and new therapeutic options to clinical scenarios in the treatment of melanoma
  • Identify adverse events and appropriate management strategies associated with immunotherapy treatment of melanoma

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Alexander M.M. Eggermont, MD, PhD
Alexander M.M. Eggermont, MD, PhD
Chief Scientific Officer, Board of Directors
Princess Máxima Center
Utrecht, The Netherlands
Professor Clinical & Translational Immunotherapy
University Medical Center / University Utrecht
Utrecht, The Netherlands

Disclosures: Consultant: BIOCAD, BioInvent, BioNTech, CatalYm, Ellipses Pharma, GSK, IO Biotech, Merck/MSD, Nektar, Novartis, Pfizer, Sellas, SkylineDx; Speakers Bureau: BIOCAD, Bristol Myers Squibb, Merck/MSD; Stock/Shareholder: SkylineDx


Jason J. Luke, MD, FACP
Jason J. Luke, MD, FACP
Director of the Cancer Immunotherapeutics Center
UPMC Hillman Cancer Center
Associate Professor of Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA

Disclosures: Research Support (all to institution for clinical trials unless noted): AbbVie, Agios (IIT), Array BioPharma (IIT), Astellas, Bristol Myers Squibb (IIT & industry), Corvus Pharmaceuticals, EMD Serono, Immatics, Incyte, Kadmon, MacroGenics, Merck, Moderna, Nektar, Numab, Replimune, Rubius Therapeutics, Spring Bank, Synlogic, Takeda, Trishula Therapeutics, Tizona, Xencor; Consultancy with compensation: AbbVie, Array BioPharma, Bayer, Bristol Myers Squibb, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Eisai, EMD Serono, KSQ Therapeutics, Janssen, Merck, Mersana, Nektar, Novartis, Pfizer, Regeneron, Ribon Therapeutics, Rubius Therapeutics, Silicon, Tesaro, Trex Bio, Werewolf Therapeutics, Xilio Therapeutics, Xencor; Scientific Advisory Board, no stock: 7 Hills Pharma, Spring Bank; Scientific Advisory Board, stock: Actym Therapeutics, Alphamab Oncology, Arch Oncology, Kanaph Therapeutics, Mavupharma, Onc.AI, Pyxis Oncology, Tempest Therapeutics; Travel: Pyxis Oncology; Patents (both provisional): Serial #15/612,657 (Cancer Immunotherapy), PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)

Jennifer McQuade, MD, MS, MA, LAc
Jennifer McQuade, MD, MS, MA, LAc
Assistant Professor
Department of Melanoma Medical Oncology
MD Anderson Cancer Center
Houston, Texas

Disclosures: Other: Honorarium-Merck, Bristol Myers Squibb, Roche

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By